About this test
Measures MGMT promoter methylation, which predicts benefit from temozolomide and longer survival in glioblastoma.
- Clinical area
- Molecular oncology
- Method
- Methylation analysis
- Sample
- FFPE tissue block
- Report languages
- EN · AR · RU
When to order
Newly diagnosed glioblastoma and high-grade glioma.
Results are reported to the ordering physician and should be interpreted in clinical context.
Request this test
Offer this test to your patients.
Contract pricing and turnaround times are provided on request for laboratories and clinics.
Molecular oncology